Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Action Myanmar and MOCRU health teams identified a number of children with rickets in remote areas of Myanmar. MOCRU director Frank Smithuis presented the findings of clinical screening to the Minister of Health, alongside treatment results and a plan for a large survey to investigate the prevalence of vitamin D deficiency and its underlying causes.

Location of 158 children with rickets in Naga region

After Medical Action Myanmar (MAM) / Myanmar-Oxford Clinical Research Unit (MOCRU) health teams had earlier found a number of children with characteristics of rickets in remote communities in north-west of Myanmar's Naga region on the Indian border, active screening in other villages in the region led to 182 children being identified with severe rickets.

A leg and its x-rayAs can be seen from the photo and the x-ray, the children, and some adults, have great difficulties walking, with some unable to walk at all. It seems that none had been diagnosed or treated earlier, possibly because their communities are extremely remote, only accessible after many hours walking.

Lab results indicated that the rickets was caused by vitamin D deficiency. Treatment with vitamin D and calcium was started immediately and follow up laboratory and X-ray investigations showed improved bone growth and bone remodelling.

After being informed of the findings, Minister of Health Dr Myint Htwe invited MAM and MOCRU to discuss the findings and local needs. On 31 May, at a follow up meeting organised by the Minister with national and regional health officials, and UN and NGO representatives, MOCRU Director Frank Smithuis presented the findings of clinical screening, patient investigations, treatment results and a plan to do a large survey in several villages in the region to investigate vitamin D deficiency prevalence and its underlying causes. The survey would include:    

  • The epidemiology and aetiology of rickets among children and pregnant women in Naga and other regions;
  • Local behaviours related to vitamin D deficiency and nutritional rickets; and
  • Potential and affordable resources of vitamin D and calcium in local communities to prevent rickets.

In addition, in cooperation with Myanmar health authorities, MOCRU/MAM proposed to:

  • Continue to screen children in Naga region and surrounding areas for rickets;
  • Treat and regularly follow up all children identified with rickets;
  • Perform blood exams and X-rays of a small patient subgroup to monitor treatment success;
  • Do community engagement to explore behaviours and raise awareness;
  • Give preventive treatment in high incidence villages for high-risk children and pregnant women.

With thanks to Frank Smithuis for text and images

Similar stories

World’s largest clinical trial for COVID-19 treatments expands internationally

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

OCGHR Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.